Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation
1 other identifier
observational
500
0 countries
N/A
Brief Summary
This post-market registry is designed to collect real world data on the use of the Globe PF System for the treatment of atrial fibrillation (AF).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2026
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 11, 2026
CompletedFirst Posted
Study publicly available on registry
June 16, 2026
CompletedStudy Start
First participant enrolled
July 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2029
June 16, 2026
June 1, 2026
3.3 years
June 11, 2026
June 11, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Effectiveness endpoint
Rate of 12-month treatment success following ablation using the Globe PF System.
12 months
Safety endpoint
Rate of subjects with one or more major adverse events up to 7 days following the index ablation procedure.
7 days
Study Arms (1)
Globe Pulsed Field System
Interventions
Ablation and atrial mapping with the Globe Pulsed Field System
Eligibility Criteria
The study population consists of AF participants who are scheduled for treatment using the Globe PF System.
You may qualify if:
- Patients with a planned ablation procedure using the commercially available Globe PF System
You may not qualify if:
- Patients whose life expectancy is 1 year or less
- Contraindication to left atrial catheter ablation or PF ablation
- Current enrollment in any investigational study of a medical device, biologic, or drug not pre-approved by Kardium
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kardium Inc.lead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 11, 2026
First Posted
June 16, 2026
Study Start
July 1, 2026
Primary Completion (Estimated)
October 1, 2029
Study Completion (Estimated)
October 1, 2029
Last Updated
June 16, 2026
Record last verified: 2026-06